Exclusive Networks Grows X-OD Reach to 9 European Markets to Introduce Complete Fortinet Security Fabric Portfolio on a Subscription Basis
22.2.2021 12:00:00 EET | Business Wire | Press release
Exclusive Networks today unveiled the latest evolution of its X-OD platform with expansion into Germany, Spain, Belgium, Finland, Austria and Ireland. This coincides with the introduction of Fortinet to the X-OD portfolio offering, with the end-to-end availability of all Fortinet solutions through the Fortinet Security Fabric on a subscription basis – a unique channel proposition in global distribution.
X-OD is now available to partners in 9 European markets (France, UK and the Netherlands already launched) with aggressive plans to extend into all global regions later this year. Exclusive Networks is growing its subscription revenues 5x faster than traditional capex-based sales, with X-OD a significant driver in the acceleration of market evolution.
“Wherever we go with X-OD, it is growing fast – now in the Nordics, Iberia and DACH, and across Benelux, UK&I and France,” said Jesper Trolle, CEO of Exclusive Networks. “The global pandemic has undoubtedly accelerated digital transformation more generally, making this proposition even more relevant to business needs. Digital customer experience, big data insights and opex-based consumption are here to stay. And our roadmap is on track to extend the capabilities of X-OD beyond Europe and into every Exclusive operating territory.”
The enhanced opportunities made possible by X-OD are particularly relevant when it comes to key technologies such as SD-WAN and market segments such as MSSP. Customer organisations face the challenge of shifting from predominantly opex-based MPLS investments into a large-scale, capex-based network evolution to SD-WAN infrastructure. These issues are negated and opportunities unlocked by X-OD-enabled consumption models.
In the case of MSSP partners who ordinarily face investing upfront in the infrastructure capabilities to drive their own managed security services, X-OD enables them to buy technology in the same way they sell it. The sheer breadth, diversity of complementary nature of Fortinet’s portfolio also benefits from X-OD’s ability to ‘subscriptionise’ products and services into discreet packages, and even allow partners to bundle these with their own service wraps that are elegantly presented to customers as a single, easy-to-consume offering. Partners benefit yet further from X-OD’s fully digital customer experience and access to rich data insights that fuel upsell/cross-sell initiatives and targeted sales campaigns.
“Fortinet’s partnership with Exclusive Networks is geared to create exceptional value and opportunity for our partners and customers,” said Patrice Perche, Chief Revenue Officer & EVP Support at Fortinet. “With X-OD, Exclusive has engineered another genuinely innovative contribution to channel dynamics that aligns with how we see the world and how we want our partners to be enabled and supported. This represents significant benefits to all levels of our partner community, and ultimately provides our customers with new ways of consuming our market-defining products and services.”
“We see fantastic opportunities for the vendors who have committed to X-OD, and are very excited to introduce Fortinet and its extensive portfolio of solutions in these early stages of worldwide rollout,” added Jesper Trolle. “We are aligned with theirs and our other vendor partners’ visions for innovation, recurring revenue and market flexibility. Together we are empowering channel partners to make a fast, safe and simple transition to subscription-based consumption both for their customers and their own business models, allowing them to sell ‘everything as a service’.”
About X-OD
X-OD is an on-demand platform that brings together and enhances all of Exclusive Networks’ products and services in one, user-friendly place. The platform is the centre of a new digitalised technology distribution ecosystem that is connecting the full value chain, bringing vendors and resellers closer to their customers.
X-OD is pivotal in enabling the shift to the subscription business model. The platform is transforming capex to opex payments, enabling technology to be bought in the same way it is sold and consumed. It is this flexibility combined with on-demand functionality, speed and simplicity that makes X-OD so relevant in a ‘customer-first’ world. www.x-od.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005043/en/
Contact information
Jemma Lowman
exclusivegroup@wearecohesive.com
01291626200
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
